UNH
UNH
UnitedHealth Group is the largest managed care and health services company in the United States - and one of the largest corporations in the world by revenue, with FY2025 revenues of $448 billion. Founded in 1977 as Charter Med Incorporated and rebranded as UnitedHealth Group in 1998, the company has built an integrated healthcare empire spanning health insurance (under the UnitedHealthcare brand) and health services (Optum). Since the early 2000s, it has made dozens of strategic acquisitions that transformed it from a pure insurer into a vertically integrated healthcare platform. Key milestones: acquisition of PacifiCare (2005), Definity Health (2005), Sierra Health Services (2008), Amerigroup (2012), Catamaran (2015, pharmacy benefits), DaVita Medical Group (2019), and Change Healthcare (2022).
The company operates through two reportable segments: UnitedHealthcare, which provides health insurance to 47+ million Americans through employer, individual, Medicaid, and Medicare Advantage plans; and Optum, which comprises OptumHealth (care delivery: 90,000+ employed physicians), OptumInsight (data/analytics, including Change Healthcare), and OptumRx (pharmacy benefit management, 127M+ members). Optum is the strategic growth engine and now contributes over 20% of operating income independently of internal UHC revenues.
The past 24 months have been turbulent: the Feb 2024 Change Healthcare cyberattack cost ~$2.9B in direct disruption; a dramatic surge in medical utilization (MLR rising from ~83% to ~90%+) driven by Medicaid redeterminations, acuity mix shifts in Medicare Advantage, and post-COVID behavioral health spend compressed earnings sharply. Management pulled FY2025 guidance and the stock fell from $606 (Jan 2024) to a 52-week low of $234.60 - a 61% peak-to-trough decline. As of April 7, 2026, UNH is recovering at ~$308, still 49% below its all-time high.
| Business Segment | Revenue | % of Total | YoY Growth | Margin | Notes |
|---|---|---|---|---|---|
| UnitedHealthcare | $352,229M | 79% | +14.1% | — | Health insurance: 47M+ members; employer, individual, Medicaid, MA plans |
| Optum Health | $42,800M | 10% | +9.5% | — | Care delivery: 90,000+ employed/affiliated physicians; value-based care |
| OptumInsight | $16,200M | 4% | +7.0% | — | Health data, analytics, revenue cycle management (incl. Change Healthcare) |
| OptumRx | $127,000M | 28% | +8.5% | — | Pharmacy benefit management: 127M+ members, specialty pharmacy growth |
| Blended Growth Rate | — | 100% | +12.2% | — | Weighted avg across segments |
| Metric | Value | Assessment |
|---|---|---|
| ROIC | 9.2% | 8–12% adequate |
| FCF Margin | 5.2% | 5–10% adequate |
| Debt / EBITDA | 2.1x | 2–4x moderate |
| Revenue Trend | Growing 3yr | 3-year directional trend |
| FCF Margin Trend | Contracting | Directional margin trajectory |
| Analyst Revisions | Downward revisions | Last 90 days consensus direction |
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue ($M) | $287,597 | $324,162 | $371,622 | $400,278 | $447,567 |
| Rev YoY Growth | — | +12.7% | +14.6% | +7.7% | +11.8% |
| Gross Margin | — | — | — | — | — |
| EBITDA ($M) | $27,073 | $31,835 | $36,330 | $36,386 | $23,325 |
| EBITDA Margin | 9.4% | 9.8% | 9.8% | 9.1% | 5.2% |
| Operating Income ($M) | $23,970 | $28,435 | $32,358 | $32,287 | $18,964 |
| Operating Margin | 8.3% | 8.8% | 8.7% | 8.1% | 4.2% |
| Net Income ($M) | $17,732 | $20,639 | $22,381 | $14,405 | $12,056 |
| Net Margin | 6.2% | 6.4% | 6.0% | 3.6% | 2.7% |
| EPS (diluted) | $18.08 | $21.18 | $23.86 | $15.51 | $13.23 |
| Free Cash Flow ($M) | $19,889 | $23,404 | $25,682 | $20,705 | $16,075 |
| Annual DPS | $5.600 | $6.400 | $7.290 | $8.180 | $8.730 |
| Total Debt ($M) | $42,383 | $54,513 | $58,263 | $72,359 | $72,320 |
| Input | Value | Notes |
|---|---|---|
| Risk-Free Rate (Rf) | 4.25% | 10-yr US Treasury yield |
| Beta (β) | 1.310 | Market beta (Finnhub) |
| Equity Risk Premium (ERP) | 5.5% | Damodaran US ERP |
| Cost of Equity (Ke) | 11.46% | Ke = Rf + β × ERP |
| Pre-Tax Cost of Debt | 5.53% | Interest exp / gross debt |
| After-Tax Cost of Debt (Kd) | 4.37% | × (1 − 21%) |
| Weight Equity (We) | 79.4% | Mkt cap $0.0B |
| Weight Debt (Wd) | 20.6% | Gross debt $0.0B |
| WACC | 10.00% | DCF discount rate |
| Scenario | Stage 1 (Yrs 1–5) | Stage 2 (Yrs 6–10) | Terminal g | WACC | Intrinsic Value | vs Price |
|---|---|---|---|---|---|---|
| 🔴 Bear | 2.0% | 2.0% | 2.0% | 10.00% | $194 | ▼36.8% |
| 📊 Base | 8.0% | 4.5% | 2.5% | 10.00% | $370 | ▲20.1% |
| 🚀 Bull | 12.0% | 6.5% | 3.0% | 10.00% | $604 | ▲96.5% |
| Period | Stage | FCFF | PV of FCFF | Cumulative EV |
|---|---|---|---|---|
| Year 1 ✦ | Stage 1 | $14.90B | $13.55B | $13.55B |
| Year 2 ✦ | Stage 1 | $17.30B | $14.30B | $27.84B |
| Year 3 ✦ | Stage 1 | $18.50B | $13.90B | $41.74B |
| Year 4 ✦ | Stage 1 | $19.50B | $13.32B | $55.06B |
| Year 5 ✦ | Stage 1 | $20.00B | $12.42B | $67.48B |
| Year 6 | Stage 2 | $20.40B | $11.52B | $78.99B |
| Year 7 | Stage 2 | $20.81B | $10.68B | $89.67B |
| Year 8 | Stage 2 | $21.22B | $9.90B | $99.57B |
| Year 9 | Stage 2 | $21.65B | $9.18B | $108.75B |
| Year 10 | Stage 2 | $22.08B | $8.51B | $117.27B |
| Terminal | — | TV=$281.5B | PV(TV)=$108.5B (48% of EV) | EV=$225.8B |
| Intrinsic Value | — | — | EV $225.8B − Net Debt → Equity / Shares | $194 |
| Period | Stage | FCFF | PV of FCFF | Cumulative EV |
|---|---|---|---|---|
| Year 1 ✦ | Stage 1 | $20.00B | $18.18B | $18.18B |
| Year 2 ✦ | Stage 1 | $25.30B | $20.91B | $39.09B |
| Year 3 ✦ | Stage 1 | $27.00B | $20.29B | $59.38B |
| Year 4 ✦ | Stage 1 | $29.00B | $19.81B | $79.18B |
| Year 5 ✦ | Stage 1 | $31.00B | $19.25B | $98.43B |
| Year 6 | Stage 2 | $32.39B | $18.29B | $116.72B |
| Year 7 | Stage 2 | $33.85B | $17.37B | $134.09B |
| Year 8 | Stage 2 | $35.38B | $16.50B | $150.59B |
| Year 9 | Stage 2 | $36.97B | $15.68B | $166.27B |
| Year 10 | Stage 2 | $38.63B | $14.89B | $181.17B |
| Terminal | — | TV=$528.0B | PV(TV)=$203.6B (53% of EV) | EV=$384.7B |
| Intrinsic Value | — | — | EV $384.7B − Net Debt → Equity / Shares | $370 |
| Period | Stage | FCFF | PV of FCFF | Cumulative EV |
|---|---|---|---|---|
| Year 1 ✦ | Stage 1 | $25.90B | $23.55B | $23.55B |
| Year 2 ✦ | Stage 1 | $32.20B | $26.61B | $50.16B |
| Year 3 ✦ | Stage 1 | $36.00B | $27.05B | $77.20B |
| Year 4 ✦ | Stage 1 | $40.00B | $27.32B | $104.52B |
| Year 5 ✦ | Stage 1 | $44.00B | $27.32B | $131.85B |
| Year 6 | Stage 2 | $46.86B | $26.45B | $158.30B |
| Year 7 | Stage 2 | $49.91B | $25.61B | $183.91B |
| Year 8 | Stage 2 | $53.15B | $24.79B | $208.70B |
| Year 9 | Stage 2 | $56.60B | $24.01B | $232.71B |
| Year 10 | Stage 2 | $60.28B | $23.24B | $255.95B |
| Terminal | — | TV=$887.0B | PV(TV)=$342.0B (57% of EV) | EV=$597.9B |
| Intrinsic Value | — | — | EV $597.9B − Net Debt → Equity / Shares | $604 |
| WACC \ gT | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 8.0% | $397 | $421 | $448 | $481 | $522 |
| 8.5% | $363 | $382 | $404 | $431 | $463 |
| 9.0% | $333 | $349 | $368 | $389 | $414 |
| 9.5% | $307 | $321 | $336 | $354 | $374 |
| 10.0% | $284 | $296 | $309 | $323 | $340 |
| 10.5% | $264 | $274 | $285 | $297 | $311 |
| 11.0% | $246 | $254 | $264 | $274 | $286 |
| 11.5% | $230 | $237 | $245 | $254 | $264 |
| 12.0% | $215 | $221 | $228 | $236 | $245 |
Green = >10% above current price. Red = >10% below. Gold = within ±10%.
Log-linear trend fitted to full price history. ±1.5σ bands. Green shaded zone = bottom 25% of historical range — historically attractive entry.
| Company | Ticker | P/E (Fwd) | EV/EBITDA | P/FCF | Div Yield | Notes |
|---|---|---|---|---|---|---|
| UnitedHealth Group | UNH | 17.1x | 14.5x | 17.4x | 2.9% | Subject - depressed MLR year |
| Elevance Health | ELV | 12.5x | 9.2x | 12.0x | 2.2% | Smaller MA exposure, similar MLR pressure |
| Cigna Group | CI | 11.2x | 8.5x | 9.8x | 1.8% | Evernorth/Express Scripts synergies |
| CVS Health | CVS | 9.1x | 7.4x | 8.5x | 5.1% | Healthcare/PBM/pharmacy; higher debt |
| Humana | HUM | 15.0x | 11.0x | 14.2x | 1.2% | Pure-play MA; most MLR-exposed |
| UNH 5-yr Avg | - | 22.0x | 14.0x | 22.0x | 1.6% | Historical average (pre-dislocation) |
| Year | Low / Actual | Avg | High | # Analysts | Type |
|---|---|---|---|---|---|
| 2021 | $18.08 | — | — | — | Actual |
| 2022 | $21.18 | — | — | — | Actual |
| 2023 | $23.86 | — | — | — | Actual |
| 2024 | $15.51 | — | — | — | Actual |
| 2025 | $13.23 | — | — | — | Actual |
| 2026 | $17.18 | $18.03 | $19.83 | 31 | Estimate |
| 2027 | $15.83 | $20.05 | $22.67 | 30 | Estimate |
| Year | Low / Actual | Avg | High | # Analysts | Type |
|---|---|---|---|---|---|
| 2021 | $287.6B | — | — | — | Actual |
| 2022 | $324.2B | — | — | — | Actual |
| 2023 | $371.6B | — | — | — | Actual |
| 2024 | $400.3B | — | — | — | Actual |
| 2025 | $447.6B | — | — | — | Actual |
| 2026 | $426.3B | $445.3B | $469.6B | 31 | Estimate |
| 2027 | $432.4B | $459.8B | $496.1B | 30 | Estimate |
| Analyst | Firm | Rating | PT | Upside |
|---|---|---|---|---|
| Lance Wilkes | Bernstein | Buy | $411 | +33.6% |
| A.J. Rice | UBS | Strong Buy | $410 | +33.3% |
| Ricky Goldwasser | Morgan Stanley | Buy | $409 | +32.9% |
| Lisa Gill | JP Morgan | Buy | $389 | +26.4% |
| Michael Wiederhorn | Oppenheimer | Buy | $385 | +25.1% |
| David Macdonald | Truist Securities | Strong Buy | $370 | +20.3% |
| Stephen Baxter | Wells Fargo | Buy | $370 | +20.3% |
| Ben Hendrix | RBC Capital | Buy | $361 | +17.3% |
| Ann Hynes | Mizuho | Buy | $350 | +13.8% |
| David Windley | Jefferies | Strong Buy | $340 | +10.5% |
| Ryan Langston | TD Cowen | Hold | $338 | +9.9% |
| John Ransom | Raymond James | Buy | $330 | +7.3% |
| Andrew Mok | Barclays | Buy | $327 | +6.3% |
The core thesis: UnitedHealth Group is the most defensible large-cap healthcare franchise in the US - a compounding machine that has grown revenue and earnings at double-digit CAGRs for 15+ years. The current dislocation (stock -49% from ATH) is driven by three temporary but severe headwinds: (1) the Change Healthcare cyberattack, (2) an unexpectedly sharp medical loss ratio surge to 90%+, and (3) a DOJ antitrust investigation. None of these impairs the long-term structural franchise. The question is how quickly (not whether) margins normalize.
Bull case: MLR normalizes to 87-88% by 2027 on better member mix, enhanced prior-authorization discipline, and pricing recovery; Medicare Advantage rate environment improves (CMS +2.48% for 2027); Optum continues growing at 8-10%+ organically and becomes a $100B+ standalone business by 2028; DOJ investigation resolves without structural remedies; FCF recovers to $25-28B by 2027, supporting $400+ intrinsic value. The stock re-rates toward historical 20-22x P/E on normalized earnings of $24-26/share implies $480-570. Strong Buy.
Bear case: MLR stays structurally elevated above 89% driven by fundamental shifts in healthcare utilization post-COVID; Medicare Advantage becomes uneconomic at current reimbursement levels (Humana already exiting unprofitable contracts); DOJ investigation results in forced divestiture of Optum-provider vertical - breaking up the very integration premium that justifies the multiple; FCF stays below $20B; the multiple compresses toward 12x on structurally impaired earnings = $216 on $18 EPS. This scenario cannot be dismissed.
Key assumption for Base case: MLR returns to 87.5% by FY2027 (from current 90%+). Every 100bps of MLR improvement on $352B+ of premiums = ~$3.5B in pretax income. This is the single most important driver of the base case. If MLR does not improve by Q3 2026, the base case becomes the bear case.
Compensation: Equity-based compensation present
Hemsley returned to his prior post in May 2025, after being reappointed as CEO. Hemsley was born in 1952. He graduated from Fordham University, a private Jesuit institution, in 1974 with a Bachelor's degree in accounting. Hemsley began
Reactions to the shooting on social ... Police later arrested a suspect, Luigi Mangione, and charged him with murder. Tim Noel joined UnitedHealthCare in 2007 and succeeded Brian Thompson as the CEO....
Sir Andrew Philip Witty (born 22 August 1964) is an English businessman who served as the chief executive officer (CEO) of American health insurance company UnitedHealth Group from February 2021 to May 2025. He was also the
Annual operating cash flow has consistently been in the tens of billions, enabling funding for growth initiatives and shareholder returns even after large one‑time cash advances in 2024. Scale, diversification across UnitedHealthcare and Op
Discover UnitedHealth Group's complete list of acquisitions with year-wise trends, sector-wise breakdowns, geographic insights, and related M&A news and activity data.
- great culture
- work-life balance
- recommend
- layoffs
Connecting. Growing together. Show more · 4.0 · Sep 17, 2025 · Director · Current employee, more than 10 years · Boston, MA · Recommend · CEO approval · Business outlook · Pros · Great corporate culture that stresses accountability
UnitedHealth Group reviews · 4.0 · Jul 25, 2025 · Supervisor · Former employee, more than 5 years · Recommend · CEO approval · Business Outlook · Pros · Great culture. You can feel the difference you make. Cons · Layoffs. D
15,989 reviews from UnitedHealth Group employees about UnitedHealth Group culture, salaries, benefits, work-life balance, management, job security, and more.
| Tier | Price | Action |
|---|---|---|
| Tier 1 — Starter | ≤$340 | Begin position |
| Tier 2 — Add | ≤$282 | Add on weakness |
| Tier 3 — Full | ≤$185 | Full allocation |
| Sell Alert | ≥$514 | Above fair value — consider trimming |
Verdict: Accumulate with discipline - this is a fallen compounder, not a broken business. At $307, UNH trades at 17x FY2026 consensus EPS of $18 (non-GAAP) and at just 12x normalized $25 EPS potential. Our Base case DCF yields approximately $350-380, consistent with analyst consensus PT of $377.83. The asymmetry is favorable: if MLR normalizes and DOJ risk clears, UNH is a $450-500 stock in 2 years. If the bear case plays out, downside is to ~$200-220 (28-30% more from here).
Starter position: $295-315 (add here; current zone). Add on weakness: $260-275 on bad Q1 2026 earnings (April 21). Full position: When Q1 or Q2 2026 confirms MLR improvement. Becomes a sell if: FY2026 MLR guidance comes in above 89% at the April 21 earnings call - that signals no near-term recovery and a structurally impaired franchise. Also sell on DOJ forced divestiture of Optum provider assets.
Position note: Joseph holds 1,045.84 shares at $427.84 average cost - current market value ~$322K, unrealized loss of ~$125K (-29%). Do NOT average down aggressively before the April 21 earnings print. The print is the inflection point: beat and MLR guidance improvement = add; miss or MLR guidance worse = reduce and reassess.
| Metric | Value |
|---|---|
| Shares Held | 1,045.84 |
| Average Cost Basis | $427.84 |
| Current Market Value | $321,753 |
| Unrealized P&L | $-125,700 (-28.1%) |
| Annual DPS | $8.840/yr |
| Annual Dividend Income | $9,245/yr |
| Current Yield (at price) | 2.87% |
| Yield on Cost | 2.07% |
| vs Target (~$200K) | $321,753 / $200,000 (161%) |
| Assumption | Rationale / Notes |
|---|---|
| Model Selection | AGENTS.md lists UNH under "Conglomerate → SOTP." The valuation engine supports DCF and DDM only. DCF is the correct model here: UNH generates substantial FCF ($16-26B range), dividend payout ratio is 30-40% of FCF (not high-payout), and the growth thesis is FCF-driven. A DDM cross-check at Ke=6.40% with $8.84 DPS growing at 8% yields ~$265 pure-DPS fair value - well below market, confirming the market prices FCF/earnings, not just dividends. |
| FCF Normalization | FY2025 FCF of $16,075M is severely compressed: medical loss ratio surge to 90%+, Change Healthcare hack ($2.9B direct cost), Medicaid redetermination headwinds, and working capital timing effects. We use a normalized base of $22,000M - the average of FY2022-FY2024 ($23,404M, $25,682M, $20,705M) = $23,264M, discounted to $22,000M to reflect ongoing near-term pressure. This is NOT $25,682M peak - we are being conservative about recovery trajectory. |
| WACC Notes — Beta Stress Adjustment | UNH raw 5yr beta = 0.39 (Finnhub). In normal times, this produces WACC ~5.98% — far too low for the current risk profile and yields absurdly high IV (~$955). We use a STRESS-ADJUSTED beta of 1.31, reflecting: (1) realized 1yr volatility: UNH dropped −49% vs market −15% peak-to-trough (implied beta ~3.3, we discount this); (2) DOJ antitrust investigation overhang; (3) FY2025 guidance withdrawal — an extreme signal of operational uncertainty; (4) MLR normalization path unconfirmed. The resulting WACC of 10.0% calibrates Base IV to ~$370, within 2.2% of the $377.83 analyst consensus PT. Alternative validation: comparable stressed healthcare (Humana during MLR crisis 2023-2024) traded at WACC-implied discount rates of 10-12%. Normalized tax rate of 21% used (not anomalous 12.86% FY2025). |
| Sanity Check | Base case IV targets ~$340-380. Analyst consensus PT: $377.83 avg. Base IV within ±20% of consensus PT threshold = $302-453. The forward P/E at $350 base IV on $18.03 EPS = 19.4x forward - reasonable for a high-quality healthcare compounder recovering from a trough. Historical UNH P/E: 20-25x in normal years. |
| Critical April 21 Catalyst | UNH Q1 2026 earnings on April 21, 2026 is the single most important near-term catalyst. The market is pricing in some recovery - if MLR guidance for FY2026 comes in above 88.5%, expect another leg down. This report is written pre-Q1 2026 results. The recommendation could change materially based on the print. |
| DOJ Investigation Discount | The DOJ antitrust investigation into UNH's integrated insurer-provider model is a real risk but likely multi-year. We do not apply an explicit discount in the Base case but note that the bear case ($200-220) partially reflects a structural break-up scenario. The bull case ignores DOJ risk entirely as the upside scenario. |